This phase I/II trial showed that infusion of CAR NK cells induced complete remission in 7 of 11 patients with CD19-positive lymphoid tumors, and all the patients are well tolerable without any dose-limiting toxicity [13]. The gene discussed is CD19; the disease is lymphoid neoplasm.